| Autor: |
Carvallo, Alvaro, Sánchez‐Fernández, Sergio, Morales‐Palacios, María de la Paz |
| Předmět: |
|
| Zdroj: |
Allergy; Feb2023, Vol. 78 Issue 2, p603-605, 3p |
| Abstrakt: |
However, only 39% of these patients achieve control with standard doses.[3] Among those who are non-respondent, up-dosing H SB 1 sb -antihistamines proves effective in 63% of patients. Chronic spontaneous urticaria (CSU) is defined by the presence of wheals with or without angioedema for more than 6 weeks, where no precipitating cause is identified.[1] Its physiopathology includes type I autoimmunity, with immunoglobulin E (IgE) autoantibodies against self-antigens, as well as type IIb autoimmunity, which involves the presence of IgG autoantibodies against IgE or the high-affinity IgE receptor, Fc RI.[2] H SB 1 sb -antihistamines remain the first-line treatment of CSU. BTK shows promise as a therapeutic target in CSU, particularly in patients with type IIb autoimmunity on which achieving control remains a challenge. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text